Accelerate your success with insights from a multidisciplinary team of healthcare strategy, regulatory affairs, population health, patient engagement, and interoperability experts. These timely discussions can help you navigate challenges from COVID-19 and the “new normal” to value-based care.
Alzheimer’s disease affects 6.2 million Americans each year so the recent approval by the FDA of Biogen’s drug Aduhelm was met with hope by many patients and their advocates. The approval process used by the FDA, the efficacy data compiled to date, and the expected annual cost of the drug have created a swirl of controversy around the decision. In this episode of the NextGen Advisors podcast, Graham Brown and Dr. Betty Rabinowitz discuss the drug’s approval and the concerns, hopes and implications it has raised.
Connect with listeners
Podcasters use the RadioPublic listener relationship platform to build lasting connections with fansYes, let's begin connecting
Find new listeners
Understand your audience
Engage your fanbase